Citation Impact
Citing Papers
Comprehensive Assessment of Genetic and Molecular Features Predicting Outcome in Patients With Chronic Lymphocytic Leukemia: Results From the US Intergroup Phase III Trial E2997
2007
Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia
2002 Standout
Phase III Trial of Fludarabine Plus Cyclophosphamide Compared With Fludarabine for Patients With Previously Untreated Chronic Lymphocytic Leukemia: US Intergroup Trial E2997
2007
Cancer statistics, 2022
2022 Standout
The Lysosomotropic Agent, Hydroxychloroquine, Delivered in a Biodegradable Nanoparticle System, Overcomes Drug Resistance of B-Chronic Lymphocytic Leukemia Cells In Vitro
2010
Cancer statistics, 2023
2023 Standout
Cancer statistics, 2020
2020 Standout
Cancer statistics, 2024
2024 Standout
Cancer treatment and survivorship statistics, 2022
2022 Standout
Cancer Statistics, 2021
2021 Standout
The prevalence and outcomes of frailty in older cancer patients: a systematic review
2014
Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial
2007
Biochemistry and pathophysiology of intravascular and intracellular lipolysis
2013
Perspectives on cancer therapy-induced mucosal injury
2004 Standout
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
2002 Standout
The perilipin family of lipid droplet proteins: Gatekeepers of intracellular lipolysis
2017 Standout
Hydroxychloroquine: From Malaria to Autoimmunity
2011 Standout
Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia
2012
Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
2001 Standout
Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia
2015
Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia
2002
Evaluating treatment strategies in chronic lymphocytic leukemia
2001
Cancer genes and the pathways they control
2004 Standout
Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
2011 Standout
Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)
2004
Chemotherapy and the war on cancer
2005 Standout
Four deaths and a funeral: from caspases to alternative mechanisms
2001 Standout
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
2010 Standout
Chronic Myelogenous Leukemia
2002
Fear of cancer recurrence in adult cancer survivors: a systematic review of quantitative studies
2013 Standout
Fludarabine Compared with Chlorambucil as Primary Therapy for Chronic Lymphocytic Leukemia
2000
Frailty: implications for clinical practice and public health
2019 Standout
Due to low infection rates no routine anti‐infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine‐based first line therapy
2006
CD47 ligation induces caspase-independent cell death in chronic lymphocytic leukemia
1999
Non-Hodgkin lymphoma
2012
The functions of thrombospondin-1 and-2
2000 Standout
What We Talk About When We Talk About Fat
2014 Standout
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
2006 Standout
Energy Metabolism in the Liver
2014 Standout
A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia
2004
The physician–patient relationship and quality of life: Lessons from chronic lymphocytic leukemia
2008
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
2008 Standout
Fludarabine phosphate for the first-line treatment of chronic lymphocytic leukaemia
2009
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
2011 Standout
Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors
2002
Pentostatin, Cyclophosphamide, and Rituximab Is an Active, Well-Tolerated Regimen for Patients With Previously Treated Chronic Lymphocytic Leukemia
2006
2016 US lymphoid malignancy statistics by World Health Organization subtypes
2016 Standout
Nitric oxide and the immune response
2001 Standout
Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies
2017 StandoutNobel
Fludarabine in the treatment of chronic lymphocytic leukemia: a review
2009
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
2016 Standout
Toward the potential cure of leukemias in the next decade
2018
Screening for hyperglycaemia in pregnancy: a rapid update for the National Screening Committee
2010 StandoutNobel
An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology.
1999
Cancer treatment and survivorship statistics, 2016
2016 Standout
Cancer treatment and survivorship statistics, 2019
2019 Standout
Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT
2005 Standout
Predictive value of serum thymidine kinase level for Ig-V mutational status in B-CLL
2003
Health-Related Quality of Life in Younger Patients With Chronic Lymphocytic Leukemia Treated With Fludarabine Plus Cyclophosphamide or Fludarabine Alone for First-Line Therapy: A Study by the German CLL Study Group
2007
Select High-Risk Genetic Features Predict Earlier Progression Following Chemoimmunotherapy With Fludarabine and Rituximab in Chronic Lymphocytic Leukemia: Justification for Risk-Adapted Therapy
2005
Chemotherapeutic Options in Chronic Lymphocytic Leukemia: a Meta-analysis of the Randomized Trials
1999
Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Advanced Chronic Lymphocytic Leukemia
2005
Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial
2008
B-Cell Chronic Lymphocytic Leukemia Cells Express a Functional Inducible Nitric Oxide Synthase Displaying Anti-Apoptotic Activity
1998
Works of Brigitte Dreyfus being referenced
IGHV gene mutational status and LPL/ADAM29 gene expression as clinical outcome predictors in CLL patients in remission following treatment with oral fludarabine plus cyclophosphamide
2009
Chlorambucil in Indolent Chronic Lymphocytic Leukemia
1998
High efficacy with five days schedule of oral fludarabine phosphate and cyclophosphamide in patients with previously untreated chronic lymphocytic leukaemia
2008
Cytogenetic Remissions in Chronic Myelogenous Leukemia Using Interferon Alpha-2a and Hydroxyurea with or without Low-Dose Cytosine Arabinoside
1991
Proliferative Response of B Chronic Lymphocytic Leukemia Lymphocytes Stimulated with IL2 and Soluble CD23
1994
Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients
2001
Cytogenetics and molecular analysis in chronic myelogenous leukemia patients treated by interferon and chemotherapy.
1990
Who needs a comprehensive geriatric assessment? A French Onco-Geriatric Screening tool (OGS)
2011